News - Part 3

LAUREATE PHARMA INC. ENTERS INTO AGREEMENT TO SELL ITS TOTOWA, NJ OPERATIONS TO DISCOVERY LABORATORIES FOR $16.0 MILLION

Laureate to Expand Its Bioprocessing Services at Princeton, NJ Facility Princeton, NJ – December 28, 2005 – Laureate Pharma, Inc., a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, announced today that it had agreed to sell its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash.  The transaction is expected to close shortly. Laureate Pharma is a wholly-owned subsidiary of Safeguard Scientifics, Inc….

Laureate Pharma and Enobia Pharma Announce Development and Manufacturing Agreement on Therapeutic Enzyme Product

PRINCETON, NJ – September 21, 2005 – Laureate Pharma, Inc. and Enobia Pharma, Inc. announced today that they have entered into a biopharmaceutical development and manufacturing agreement for process development and manufacture of cGMP batches of Enobia’s recombinant enzyme sPHEX Metallo Peptidase. The project is well underway and Laureate Pharma expects to supply Enobia with material for their Phase I clinical trials 3Q 2006. Terms of the agreement were not…

Michael Cavanaugh Joins Laureate Pharma To Lead Sales, Marketing and Business Development Activities

PRINCETON, N.J. and GIBBSTOWN, N.J., September 7th, 2005 — Laureate Pharma, Inc. announced the appointment of Michael J. Cavanaugh as Vice President of Sales, Marketing and Business Development. In this newly created position, Mr. Cavanaugh will be responsible for Laureate’s worldwide sales and marketing and business development activities supporting the company’s contract development, manufacturing and bioprocessing business. “We are delighted to welcome Michael to Laureate’s management team,” said Robert J….

LAUREATE PHARMA, INC. AND EMD CHEMICALS INC. TEAM UP FOR STRATEGIC COLLABORATION

PRINCETON, N.J. and GIBBSTOWN, N.J., March 3 /PRNewswire/ — Laureate Pharma, Inc. and EMD Chemicals Inc. announced today that they have entered into a strategic collaboration for the co-marketing and promotion of biopharmaceutical products and services. Under the agreement, EMD Chemicals will utilize its expertise in packing and testing large-scale ion exchange chromatography columns in combination with Laureate Pharma’s expertise in protein process development, production, and purification to further penetrate…

Laureate Pharma Sees Bright Future As Newest Safeguard Scientifics Company

PRINCETON, N.J., Jan. 7, 2005 /PRNewswire/ — Laureate Pharma is pleased to announce that the company has been acquired by Safeguard Scientifics, Inc. (NYSE: SFE – News), a strategic growth partner for companies in the Time-to-Volume stage of development. Laureate Pharma will continue to serve its clients in the growing biopharmaceutical and pharmaceutical contract manufacturing services industry. (Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO ) In addition to expansion capital, Safeguard Scientifics provides its companies…

Safeguard Scientifics Completes Acquisition of Laureate Pharma

WAYNE, PA, December 6, 2004 — Safeguard Scientifics, Inc. (NYSE: SFE) announced today that it had completed the acquisition of the business and substantially all of the assets of Laureate Pharma L.P. of Princeton, NJ for approximately $29.5 million. Laureate Pharma is a bioprocessing and drug delivery services company dedicated to supporting the development and commercialization of new pharmaceuticals and diagnostics. Anthony L. Craig, President and Chief Executive Officer of…

Laureate Pharma L.P. Announces Operation of 2500 Liter Bioreactor

PRINCETON, NJ – June 3, 2004 – Laureate Pharma L.P. announces its recently installed 2500-Liter stirred tank bioreactor is validated and fully operational. The bioreactor, with an overall working volume of 2000-Liters, has been installed in a new cGMP production suite, extensively validated and suitable for cGMP manufacture of kilogram quantities of biopharmaceutical products such as monoclonal antibodies and other recombinant proteins. In addition, Laureate has increased the capacities of…

GTC BIOTHERAPEUTICS AND LAUREATE PHARMA ENTER STRATEGIC COLLABORATION

FRAMINGHAM, MA and PRINCETON, NJ – March 9, 2004 — GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) and Laureate Pharma L.P. (“Laureate Pharma”) have entered into a strategic collaboration for serving the clinical and commercial development, production, and purification needs of the biopharmaceutical industry. GTC and Laureate Pharma will coordinate their industry marketing efforts to provide strategic access to clients for recombinant protein production services required from small scale through tonnage…

Laureate Pharma L.P. announces technology transfer and manufacturing agreement with Discovery Laboratories, INC.

PRINCETON, NJ – January 21, 2004 – Laureate Pharma L.P. announces entering into a manufacturing agreement with Discovery Laboratories, Inc. Under the contract, Laureate Pharma will provide manufacturing services that support Discovery Laboratories’ product requirements. Terms of the agreement were not disclosed. In the first phase of the manufacturing implementation plan, Discovery has transferred its existing manufacturing equipment to Laureate’s microparticle manufacturing facility located in Totowa, N.J. Project plans include…

Laureate Pharma and FeRx Announce Manufacturing Service Agreement

PRINCETON, NJ – October 14, 2003 – Laureate Pharma L.P. and FeRx, Inc. announce a manufacturing and services agreement for FeRx Incorporated’s MTC-DOX product. Under the contract, Laureate Pharma will provide formulation and filling services to support FeRx’s clinical development programs. Terms of the agreement were not disclosed. “We are delighted to be working with FeRx. There is an excellent fit between FeRx’s technology and Laureate’s capabilities in microparticle manufacturing,”…